Skip to content
value.today

Akorn

AKRXQUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$682 M
For year ending December-2019
Net income
$-227 M
-33.2% margin
SEC filing
Employees
—

Akorn in brief

Akorn is an unlisted company in the Biotechnology industry, based in Lake Forest, USA. In the year to December 2019 it had sales of $682 M and a net loss of $227 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Akorn

Akorn Operating Company LLC (Akorn Inc. prior to its bankruptcy) was an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. The company dealt in developing, manufacturing and marketing of generic and prescription drugs as well as animal and consumer health products. It was a component of the NASDAQ Biotechnology Index.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Akorn timeline

1 events, 1995
  1. 1995
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Akorn from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Akorn

Acquisitions and changes
No longer listed: it is not in the SEC's, Nasdaq Trader's and FINRA's lists of US-traded securities (checked 14 November 2026); its SEC filings show that it ended its SEC registration (Form 15) on 2 October 2020.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-33.2%
Operating margin
-27.6%
Return on equity
-96.8%
Liabilities / assets
81.8%
Net debt
$-145M
Revenue growth
-1.7%
R&D / revenue
5.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2012: revenue $256M, net income $35M$256MFY12Fiscal year ending Dec 2013: revenue $318M, net income $52M$318MFY13Fiscal year ending Dec 2014: revenue $555M, net income $14M$555MFY14Fiscal year ending Dec 2015: revenue $985M, net income $151M$985MFY15Fiscal year ending Dec 2016: revenue $1.1B, net income $184M$1.1BFY16Fiscal year ending Dec 2017: revenue $841M, net income $-25M$841MFY17Fiscal year ending Dec 2018: revenue $694M, net income $-402M$694MFY18Fiscal year ending Dec 2019: revenue $682M, net income $-227M$682MFY19
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2019$682M-1.7%$-188M$-227M-33.2%
Dec 2018$694M-17.5%$-388M$-402M-57.9%
Dec 2017$841M-24.7%$-23M$-25M-2.9%
Dec 2016$1.1B+13.4%$323M$184M16.5%
Dec 2015$985M+77.5%$295M$151M15.3%
Dec 2014$555M+74.7%$61M$14M2.5%
Dec 2013$318M+24.0%$88M$52M16.5%
Dec 2012$256M—$69M$35M13.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2019$-37M$30M$-67M——
Dec 2018$-69M$69M$-138M$-3.21—
Dec 2017$248M$95M$152M$-0.20—
Dec 2016$167M$75M$92M$1.47—
Dec 2015$298M$28M$270M$1.22—
Dec 2014$40M$30M$11M$0.13—
Dec 2013$57M$12M$46M$0.46—
Dec 2012$26M$20M$6M$0.32—

SEC filings

Official filings of Akorn with the US Securities and Exchange Commission.

Annual results

Revenue
$682 M
Operating income
$-188 M
Net income
$-227 M

For year ending December-2019 · source: SEC filing

Balance sheet

Total assets
$1.3 B
Total liabilities
$1.1 B
Total equity
$234 M

As of December-2019

Insider trading at Akorn#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
Akorn: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jonathan KaferEVP & Chief Commercial OfficerShares withheld for tax-281$0.030$8178,911Form 4
filed Randall E. PollardSVP, Finance & CAOShares withheld for tax-256$0.030$898,910Form 4
filed Joseph BonaccorsiEVP Gen Counsel & SecretaryShares withheld for tax-997$0.030$30972,838Form 4
filed Randall E. PollardSVP, Finance & CAOShares withheld for tax-2,742$0.250$68699,166Form 4
filed Joseph BonaccorsiEVP Gen. Counsel & SecretaryShares withheld for tax-14,983$0.250$4 K973,835Form 4
filed Duane A. PortwoodEVP & Chief Financial OfficerShares withheld for tax-15,376$0.250$4 K344,701Form 4
filed Jonathan KaferEVP & Chief Commercial OfficerShares withheld for tax-9,539$0.250$2 K179,192Form 4
filed Randall E. PollardSVP, Finance & CAOShares withheld for tax-622$0.260$162101,908Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Akorn#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2017
$0M
Q4 2017

Bankruptcy filing: (8-K); (8-K); (8-K)

Akorn share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2017Q4 2017$0M
Q4 2016Q4 2016$20M
Q4 2015Q4 2016$0M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Akorn scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in financial health (2 of 4), weakest in growth (0 of 5). Fiscal year 2019.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 5
    • ✗Revenue grew in the newest year-1.7%Revenue down 1.7% in fiscal 2019.
    • ✗Revenue up more than 5% a year over three years-15.1%-15.1% a year over the three years to fiscal 2019.
    • ✗Faster growth over three years than its peers' median-15.1%-15.1% a year against Biotechnology's median of 12.9% (181 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$227 M-$227 M in fiscal 2019 against $14 M in 2014.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2019.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$227 MNet income -$227 M in fiscal 2019.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2019.
    • ✓Operating margin above its peers' median-27.6%-27.6% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-66.9%-66.9% in fiscal 2019.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-27.6%-27.6% in fiscal 2019 against 28.9% in 2016.
  • Financial health2 of 4
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.49 at the end of fiscal 2019.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2019.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $145 M at the end of fiscal 2019.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2019.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Akorn: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Akorn: statements by fiscal year
PeriodTrendFY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011FY 2010to Dec 31, 2010
Income statement
Revenue6826948411,117985555r31825613786
Cost of revenue430448409r443r389294r1461075744
Gross profit253246432r674r596261r1721498042
Research and development384745r39r4131r2016127.0
Selling, general and administrative274280r216r198r16293r544832r23
Operating expenses441634455r351r301201r84804631
Operating income−188−388−23r323r29561r88693311
Interest expense and finance costs———————6.42.1r0
Share of profit of associates——————0.101523r
Other non-operating income (expense)1.21.47.0r2.0r−7.00.9r0.4———
Income before tax−288−438−5927123225r83584122
Income tax−61−36−35878111r3122−1.70.2
Income from continuing operations——−2518415114r5235——
Income from discontinued operations———00−0.5r————
Net income attributable to shareholders−227−402−2518415114r52354322
Earnings per share, basic—-3.21-0.201.501.290.13r0.540.370.450.24
Earnings per share, diluted—-3.21-0.201.471.220.13r0.460.320.410.22
Shares, weighted average (basic)—125125123117103969595r93r
Shares, weighted average (diluted)126125125126126110r114111104r99r
Balance sheet
Cash and cash equivalents14522536820134671r3441r8442
Receivables134153141283151188r65512511
Inventory170174184175185135r56523519
Other current assets30r3237262037r5.85.23.11.8
Current assets480584730686708r476r16915915674
Property, plant and equipment296335313238180144r82814433
Right-of-use (leased) assets22—————————
Goodwill268284285284285285r3032120
Other intangible assets216285569759865r705r11664683.1
Non-current assets—5778661,0501,1551,2691811301074.8
Total assets1,2891,4951,9101,9742,043r1,894r432370307111
Accounts payable454052604647r2322184.9
Debt due within a year8430—053r10————
Current liabilities986171171176231r151r61432822
Long-term debt0820815810994r1,1141091051010
Lease liabilities (non-current)22—————————
Non-current liabilities698819079791,190r1,387r1101251212.4
Total liabilities1,0541,0511,0781,1551,421r1,538r17216814924
Retained earnings−334−10729531918029r15−37−72−115
Shareholders' equity234444831819622356r260201158r87
Total liabilities and equity1,2891,4951,9101,9742,043r1,894r432370307111
Shares outstanding12612512512411911297969594
Cash-flow statement
Depreciation and amortization708385888758r14115.25.0
Share-based compensation21222115137.8r7.17.05.22.7
Cash from operating activities−37−69248r167r29840r572620r12
Capital expenditure−30−69−95−75−28−30r−12−20−12r−4.7
Intangible assets bought−0.1−0.1−0.2−4.0−3.8−8.9r————
Cash from investing activities−30−69−91−73−54−967r−67−76−95r32
Debt issued———001,045————
Debt repaid—00−200−10−85————
Shares bought back—00−4500————
Cash from financing activities−13−5.07.6−24032963r3.16.4118−3.8
Exchange-rate effect on cash0.1−1.01.2r0.0−0.3−0.2−0.2−0.300
Change in cash−80−144166r−147r27637r−6.6−434240
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2020. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Akorn#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bankruptcy or receivership 3 · Delisting notice 2 · Debt called early 2 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 7 · New debt 3 · Unregistered share sale 2 · Shareholder rights changed 1 · Results announced 6

Akorn: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipChange in controlAcquisition or sale completedDirectors and officersShareholder rights changed8-K
Results announced8-K
Material agreement8-K
Bankruptcy or receivershipDelisting noticeMaterial agreement8-K
Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Debt called early8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K/A
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 2, 2020

FDA drug approvals: Akorn#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2005.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
0 new drugs, 1 biologics
Akorn: latest FDA approvals
ApprovedDrugKind
2005-10-25Hydasenew moleculeHyaluronidase · BLA021716Biologic (BLA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (AKORN INC), so they follow acquisitions

How Akorn compares in Biotechnology

  • Revenue$682 M · higher than 89% of 647
  • Net margin-33.2% · higher than 56% of 408
  • Revenue growth-1.7% · higher than 40% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Akorn🇺🇸——-33.2%-1.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2019
Balance sheet:
As of December-2019
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Akorn? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Akorn's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Akorn? Suggest a correction